Related Experiment Video

Updated: Nov 24, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Symptom burden in transplant ineligible patients with newly diagnosed multiple myeloma: a population-based cohort

Hira S Mian1, Gregory R Pond2, Tanya M Wildes3

  • 1Juravinski Cancer Center, Department of Oncology, McMaster University, Hamilton. hira.mian@medportal.ca.

Haematologica
|December 23, 2020
PubMed

Abstract:

Not available.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K

Related Experiment Videos

Last Updated: Nov 24, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.1K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.7K

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

647
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
647

Articles linked to this work by shared authors, journal, and citation graph.

Improving interprofessional collaboration for palliative primary care teams: results from the Canada-wide CAPACITI randomized controlled trial.

Journal of interprofessional care·2026

Two-Year Outcomes after Direct-to-Surgery in Good Prognosis Margin-Clear Stage II or III Rectal Cancer: The QuickSilver Study.

Annals of surgical oncology·2026

Patient- and caregiver-reported outcome and experience measures for evaluating serious illness communication: An environmental scan.

Palliative care and social practice·2026

Assessment of Risks and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients Including Potentially Undiagnosed Cases-A Multicenter Canadian Study.

Current oncology (Toronto, Ont.)·2026

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

NEJM evidence·2026

Family Caregivers' Perspectives on Direct Financial Support Programs: A Qualitative Exploration of Nova Scotia's Caregiver Benefit.

Canadian journal on aging = La revue canadienne du vieillissement·2026

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

Haematologica·2026

Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia".

Haematologica·2026

Successful treatment of systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition.

Haematologica·2026

Outcomes of CHOP versus CHOEP/EPOCH in aggressive adult T-cell leukemia/lymphoma: an international cohort analysis.

Haematologica·2026

Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: "First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level".

Haematologica·2026

Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients.

Haematologica·2026

Telitacicept for primary angiitis of the central nervous system: A real-world retrospective study.

Therapeutic advances in neurological disorders·2026

Nanotheranostics in orthopedic diseases: a critical review of molecular diagnostic-driven targeted therapeutics for personalized patient care.

Expert review of molecular diagnostics·2026

Limonin ameliorates hyperuricemia-induced cognitive impairment through modulation of microglial HIF-1α-driven neuroinflammation.

International immunopharmacology·2026

Beyond the skin barrier: nanocarrier-based drug delivery with emerging insights into the gut-skin axis and probiotic modulation in atopic dermatitis.

The Journal of pharmacy and pharmacology·2026

A 3D in vitro co-culture model to investigate tumor-endothelial interactions in Neurofibromatosis type 2-associated meningiomas.

Neuro-oncology advances·2026

Molecular mechanisms and translational potential of plant-derived nanovesicles in skin care and regeneration.

Frontiers in cell and developmental biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us